Japan's Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
Saved in:
Main Authors: | Akihiko Ozaki (Author), Yuki Senoo (Author), Hiroaki Saito (Author), Andy Crump (Author), Tetsuya Tanimoto (Author) |
---|---|
Format: | Book |
Published: |
Kerman University of Medical Sciences,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals
by: Hayase Hakariya, et al.
Published: (2024) -
Underperformance of Reverse-Transcriptase Polymerase Chain Reaction in Japan and Potential Implications From Diamond Princess Cruise Ship and Other Countries During the Ongoing COVID-19 Pandemic
by: Kana Yamamoto, et al.
Published: (2020) -
Japan's COVID-19 response: underutilized beds and misused funds
by: Yoshika Saito, et al.
Published: (2023) -
Defining and Acting on Global Health: The Case of Japan and the Refugee Crisis
by: Claire Leppold, et al.
Published: (2016) -
The Obesity Paradox in Cancer: Is Bigger Better?
by: Barry J.A. Laird, et al.
Published: (2022)